FFO
NKTR icon

Fortitude Family Office’s Nektar Therapeutics NKTR Stock Holding History

Fortitude Family Office’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$504 Sell
7
-14
-67% -$797 ﹤0.01% 1728
2025
Q4 		$888 Hold
21
– – ﹤0.01% 1509
2025
Q3 		$1.2K Buy
+21
New +$695 ﹤0.01% 1478

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fortitude Family Office's NKTR Position: Q1 2026 in Review

Fortitude Family Office reduced its Nektar Therapeutics (NKTR) stake by 67% in Q1 2026, selling an estimated $797 and leaving 7 shares worth $504. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Fortitude Family Office first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.2K in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Fortitude Family Office held 7 shares of Nektar Therapeutics worth $504 as of Q1 2026.
  • Fortitude Family Office sold 14 Nektar Therapeutics shares in Q1 2026, an estimated $797.
  • Nektar Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1728 holding.
  • Fortitude Family Office first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fortitude Family Office's Nektar Therapeutics position peaked at $1.2K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.